1h Free Analyst Time
The Recombinant Proteins Market size was estimated at USD 5.05 billion in 2023, USD 5.80 billion in 2024, and is expected to grow at a CAGR of 14.51% to reach USD 13.04 billion by 2030 . Speak directly to the analyst to clarify any post sales queries you may have.
The recombinant proteins are created by inserting a modified gene into an expression system such as bacteria, yeast, or mammalian cells, which then produce the desired protein with high purity and functionality. Recombinant proteins involve research, development, manufacturing, and commercialization of genetically engineered proteins derived from recombinant DNA technology. The prevalence of infectious and chronic diseases, increasing healthcare expenditure needed for new therapeutics and diagnostics, and increased R&D investments within biopharmaceutical companies are raising the need for high-quality recombinant proteins. The rapid advancements in genomics technologies and growing adoption of biologics over small-molecule drugs are resulting in increased adoption of recombinant proteins. However, the high cost of production and maintenance may adversely impact the use of recombinant DNA by the end-use industries. In addition, the emerging applications in animal reproduction and to enhance feed efficiency and significant investments in recombinant protein development are the factors expected to encourage the use of these proteins by the end-use sectors worldwide.
Regional Insights
The recombinant protein market is evolving in the Americas owing to the presence of well-established pharmaceutical and biotech companies with advanced research facilities and regulations that ensure high-quality products. Additionally, technological advancements, significant increases in funding for research and development (R&D), the rising prevalence of chronic conditions, and a surge in demand for personalized medicines are resulting in an increased need for recombinant protein in the Americas. The EMEA region represents a developing landscape for the recombinant proteins market owing to the stringent regulations implemented to use these proteins and the requirement for manufacturers to adhere to GMP standards. The recombinant proteins market is growing in the APAC region due to the prevalence of chronic diseases, increased research activities in cell biology, biochemistry, structural and biophysical studies, and the need for efficient biopharmaceuticals. Moreover, technological advancements and collaborations between biopharmaceutical companies and academic institutions are expected to increase the translation of laboratory innovations into commercially viable products and boost the adoption of recombinant proteins by the end-use sectors across the globe.Product: Significant use of adhesion molecules & receptors for research purposes
Adhesion molecules and receptors are essential for cell-cell communication, migration, and immune response regulation. They are widely used in research to understand cancer, inflammation, and infection. Growth factors and chemokines regulate cellular growth, differentiation, and migration processes. They are vital for wound healing, tissue repair, and stem cell research applications. Immune response proteins are crucial components of the immune system that regulate infection defense mechanisms and inflammation control. Researchers use the immune response proteins to study autoimmune diseases and vaccine development. Kinase proteins are essential in cellular signal transduction pathways regulating cell division, survival, metabolism, and other biological processes. Kinase proteins possess significant potential as drug targets for cancer treatment and management of chronic inflammatory conditions. Membrane proteins are crucial for cell signaling, transport, and adhesion and have applications in drug discovery and development due to their involvement in numerous physiological processes. Recombinant metabolic enzymes are vital in biological pathways regulating cellular metabolism and energy production. They are used in drug discovery efforts targeting metabolic diseases, such as diabetes or obesity. Regulatory proteins control gene expression or cellular processes such as apoptosis and cell cycle progression. They are extensively used for cancer treatment and other diseases involving uncontrolled cell growth or differentiation. Structural proteins provide mechanical support to cells and tissues while maintaining structural integrity within organisms. They find applications in biomedical research related to tissue engineering or regenerative medicine.Services: Expression services focus on high yields and compatibility with target protein characteristics
Recombinant protein cloning involves the insertion of a target gene into an appropriate expression vector, resulting in a recombinant DNA molecule that directs protein production in host cells. Need-based preferences for cloning services include high efficiency, specificity, and adaptability to different organisms. Expression refers to the process of translating a gene's information into a functional protein product. Several factors influence the choice of an expression system, such as productivity levels, compatibility with post-translational modifications (PTMs), and ease of scale-up for higher yields or purity levels required for downstream applications. Purification is essential to remove contaminants from the expressed protein and prepare it for downstream applications such as drug discovery, diagnostics, and research. Preferences for purification services include high selectivity, reproducibility, yield, and minimal sample loss. The demand for cloning services has increased due to advancements in molecular biology techniques, enabling the generation of multiple clones simultaneously. Expression services have evolved with improvements in host systems to accommodate diverse proteins with varying complexity levels. Purification services continue progressing with resin chemistry and instrumentation advances, allowing higher throughput and yields.End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies
Academic research institutes are the foundation for innovative and advanced research in recombinant protein technology. These institutes require high-quality, reliable, cost-effective recombinant proteins to study structural biology, functional studies, drug discovery, and diagnostics. Contract manufacturing organizations (CMOs) and contract research organizations (CROs) provide outsourced research and product development services to biopharmaceutical companies specializing in recombinant protein production, assay development, and preclinical testing. They value rapid turnaround times, competitive pricing structures, and customizable offerings tailored to their customer needs. Pharmaceutical biopharmaceutical companies require high-quality, GMP-compliant recombinant proteins for therapeutic and diagnostic product development. These end-user segments prioritize quality, reliability, and cost-effective solutions. Academic research institutes emphasize discovery-driven research application support; biotechnology companies value customization and scalability; CROs and CMOs prioritize turnaround time and customized offerings catering to diverse customers, while pharmaceutical and biopharmaceutical companies require robust manufacturing capabilities with strict regulatory compliance.Function: Potential demand of recombinant proteins for drug discovery & development
Recombinant proteins are essential in diagnostics, facilitating detection and monitoring of various diseases. Enzyme-linked immunosorbent assays (ELISAs) and lateral flow immunoassays are common diagnostic techniques that utilize recombinant proteins as antigens or antibodies to detect specific biomarkers associated with specific diseases. Recombinant proteins play an indispensable role in drug discovery and production of biologics, vaccines, and cell and gene therapies and serve as potential therapeutic targets or drug candidates themselves. Additionally, they facilitate high throughput screening assays to identify lead compounds targeting specific disease pathways. Diagnostic applications primarily focus on sensitivity, specificity, rapidness, and cost-effectiveness. In contrast, drug discovery & development emphasizes recombinant proteins' purity, stability, scalability, and functional activity.Market Dynamics
The market dynamics represent an ever-changing landscape of the Recombinant Proteins Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.Market Disruption Analysis
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Recombinant Proteins Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Recombinant Proteins Market.Porter’s Five Forces Analysis
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Recombinant Proteins Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.Value Chain & Critical Path Analysis
The value chain of the Recombinant Proteins Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.Pricing Analysis
The pricing analysis comprehensively evaluates how a product or service is priced within the Recombinant Proteins Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Recombinant Proteins Market.Technology Analysis
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Recombinant Proteins Market.Patent Analysis
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Recombinant Proteins Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.Trade Analysis
The trade analysis of the Recombinant Proteins Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.Regulatory Framework Analysis
The regulatory framework analysis for the Recombinant Proteins Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Recombinant Proteins Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Recombinant Proteins Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Recent Developments
iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein
U.S.-based iTolerance and Northway Biotech have agreed to manufacture Streptavidin-FasL (SA-FasL) fusion protein, a critical component of iTolerance's proprietary iTOL-100 platform technology. This collaboration is aimed to provide treatment options that have the potential to cure diseases without the need for chronic immunosuppression.Biovian Invests Over EUR 50M in Manufacturing Facility in Finland
Biovian has invested EUR 50M in expanding its manufacturing facility in Turku, Finland, to offer end-to-end services, from development to commercial-scale production, for biopharmaceuticals. The new facility spans 6,400 m2 (69,000 ft2) and has advanced technologies and equipment to cater to Advanced Therapy Medicinal Products (ATMPs), including adenoviral and AAV therapies.Fortis Life Sciences acquires International Point of Care
Fortis Life Sciences, LLC acquired International Point of Care, Inc.(IPOC) to provide customers with a comprehensive end-to-end solution for their immunodiagnostic and molecular diagnostic products. With this acquisition, Fortis can offer their customers top-quality materials and services that support advancements in ultra-high-sensitivity point-of-care diagnostics, multiplexing applications, quantitative lateral flow, isothermal amplification, and CRISPR-based diagnostics.Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Recombinant Proteins Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.Key Company Profiles
The report delves into recent significant developments in the Recombinant Proteins Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Bhat Bio-tech India Private Limited, Bio-Rad Laboratories, Inc., Biogen Inc., BioLegend, Inc. by PerkinElmer, Inc., Biologics International Corp, BPS Bioscience, Inc., Bristol-Myers Squibb Company, Creative BioMart Inc., Croyez Bioscience Co., Ltd., Eli Lilly and Company, Enzo Life Sciences, Inc., Fortis Life Sciences LLC, GenScript Biotech Corporation, GeoVax Labs, Inc., Hzymes Biotech, Johnson & Johnson Services, Inc., Laurus Labs Limited, LenioBio GmbH, Lonza Group AG, Marin Biologic Laboratories, Inc., Merck KGaA, Meridian Bioscience, Inc. by SD Biosensor Inc., Miltenyi Biotec B.V. & Co. KG, Novartis AG, ProMab Biotechnologies, Inc., Proteintech Group, Inc., Proteos, Inc., R&D Systems, Inc. by Bio-Techne Corporation, Sanofi S.A., Sartorius AG, Selvita S.A., Sino Biological, Inc., SK bioscience, Takara Bio Inc., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific, Inc..Market Segmentation & Coverage
This research report categorizes the Recombinant Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:- Product
- Adhesion Molecules & Receptors
- Growth Factors & Chemokines
- Immune Response Proteins
- Kinase Proteins
- Membrane Proteins
- Recombinant Metabolic Enzymes
- Regulatory Proteins
- Structural Proteins
- Services
- Cloning
- Expression
- Purification
- End-User
- Academic Research Institutes
- Contract Research Organizations & Contract Manufacturing Organizations
- Pharmaceutical & Biopharmaceutical Companies
- Function
- Diagnostics
- Drug Discovery & Development
- Biologics
- Cell & Gene Therapy
- Vaccines
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
This research report offers invaluable insights into various crucial aspects of the Recombinant Proteins Market:
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
5. Market Insights
6. Recombinant Proteins Market, by Product
7. Recombinant Proteins Market, by Services
8. Recombinant Proteins Market, by End-User
9. Recombinant Proteins Market, by Function
10. Americas Recombinant Proteins Market
11. Asia-Pacific Recombinant Proteins Market
12. Europe, Middle East & Africa Recombinant Proteins Market
13. Competitive Landscape
14. Competitive Portfolio
List of Figures
List of Tables
Companies Mentioned
- Abcam PLC
- Abnova Corporation
- Agilent Technologies, Inc.
- Bhat Bio-tech India Private Limited
- Bio-Rad Laboratories, Inc.
- Biogen Inc.
- BioLegend, Inc. by PerkinElmer, Inc.
- Biologics International Corp
- BPS Bioscience, Inc.
- Bristol-Myers Squibb Company
- Creative BioMart Inc.
- Croyez Bioscience Co., Ltd.
- Eli Lilly and Company
- Enzo Life Sciences, Inc.
- Fortis Life Sciences LLC
- GenScript Biotech Corporation
- GeoVax Labs, Inc.
- Hzymes Biotech
- Johnson & Johnson Services, Inc.
- Laurus Labs Limited
- LenioBio GmbH
- Lonza Group AG
- Marin Biologic Laboratories, Inc.
- Merck KGaA
- Meridian Bioscience, Inc. by SD Biosensor Inc.
- Miltenyi Biotec B.V. & Co. KG
- Novartis AG
- ProMab Biotechnologies, Inc.
- Proteintech Group, Inc.
- Proteos, Inc.
- R&D Systems, Inc. by Bio-Techne Corporation
- Sanofi S.A.
- Sartorius AG
- Selvita S.A.
- Sino Biological, Inc.
- SK bioscience
- Takara Bio Inc.
- Takeda Pharmaceutical Company Limited
- Thermo Fisher Scientific, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 182 |
| Published | May 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 5.8 Billion |
| Forecasted Market Value ( USD | $ 13.04 Billion |
| Compound Annual Growth Rate | 14.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 39 |
